Jeimi Diedrich
Family · Altamonte Springs, FLNPI 1740936228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,094, 7.6 times the $275 reported in 2022. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$518
- AstraZeneca$500
- AbbVie$407
- Bayer$352
- Novo Nordisk$342
- Johnson & Johnson$278
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,73098%
- Education$902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 32 | $518 |
| AstraZeneca(2 entities) | 22 | $500 |
| AbbVie | 20 | $407 |
| Bayer | 15 | $352 |
| Novo Nordisk | 20 | $342 |
| Johnson & Johnson(2 entities) | 7 | $278 |
| Sanofi | 5 | $274 |
| Novartis | 15 | $227 |
| Pfizer | 17 | $211 |
| UCB, Inc. | 11 | $210 |
| Astellas Pharma US Inc | 5 | $181 |
| Boehringer Ingelheim | 9 | $157 |
| Amgen | 6 | $153 |
| Mallinckrodt Hospital Products Inc. | 4 | $128 |
| Lilly USA, LLC | 6 | $92 |
| Ferring Pharmaceuticals Inc. | 3 | $88 |
| Aurinia Pharma U.S., Inc. | 4 | $84 |
| Abbott | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 3 | $77 |
| Exact Sciences | 3 | $72 |
| Phathom Pharmaceuticals, Inc. | 3 | $72 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Radius Health, Inc. | 2 | $45 |
| Sobi, Inc | 2 | $44 |
| Genentech USA, Inc. | 1 | $30 |
| Biogen | 1 | $23 |
| Sandoz | 1 | $20 |
| Invivyd Inc | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,820 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 61 | $65,056 |
| EliquisApixaban | 19 | $28,725 |
| MounjaroTirzepatide | 16 | $24,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $19,683 |
| FarxigaDapagliflozin Propanediol | 17 | $18,149 |
| JanuviaSitagliptin Phosphate | 21 | $17,373 |
| LinzessLinaclotide | 11 | $13,160 |
| OzempicSemaglutide | 14 | $12,547 |
| Pregabalin | 35 | $1,885 |
| Atorvastatin Calcium | 196 | $1,670 |
| Losartan Potassium | 154 | $1,439 |
| Rosuvastatin Calcium | 76 | $1,048 |
| Levothyroxine Sodium | 137 | $1,036 |
| Fenofibrate | 19 | $862 |
| Fluticasone Propionate | 100 | $839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $157 | $65,05661 claims |
| PfizerEliquis | $211 | $28,72519 claims |
| Lilly USA, LLCMounjaro | $92 | $24,40216 claims |
| GSKTrelegy Ellipta | $518 | $19,68324 claims |
| AstraZenecaFarxiga | $500 | $18,14917 claims |
| AbbVieLinzess | $407 | $13,16011 claims |
| Novo NordiskOzempic | $342 | $12,54714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Altamonte Springs
- Holly YoungAltamonte Springs$60K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.